Journey Medical Corporati...
3.73
-0.05 (-1.32%)
At close: Jan 14, 2025, 3:59 PM
3.73
0.00%
After-hours Jan 14, 2025, 04:00 PM EST

Company Description

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.

The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use.

It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution.

The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation.

Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Journey Medical Corporation
Journey Medical Corporation logo
Country United States
IPO Date Nov 12, 2021
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 41
CEO Claude Maraoui

Contact Details

Address:
9237 East Via de Ventura Boulevard
Scottsdale, Arizona
United States
Website https://journeymedicalcorp.com

Stock Details

Ticker Symbol DERM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001867066
CUSIP Number 48115J109
ISIN Number US48115J1097
Employer ID 47-1879539
SIC Code 2834

Key Executives

Name Position
Claude Maraoui Founder, President, Chief Executive Officer & Director
Joseph M. Benesch Chief Financial Officer & Corporate Controller
Andrew J. Zwible Vice President of Operations
Dr. Lindsay Allan Rosenwald Executive Chairman
Jaclyn Jaffe Senior Director of Corporate Operations
Ramsey Alloush General Counsel & Company Secretary

Latest SEC Filings

Date Type Title
Nov 29, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Nov 12, 2024 10-Q Quarterly Report
Nov 12, 2024 8-K Current Report
Nov 04, 2024 8-K Current Report
Aug 13, 2024 10-Q Quarterly Report
Aug 12, 2024 8-K Current Report
Aug 01, 2024 4 Filing
Jul 23, 2024 4 Filing
Jul 23, 2024 4 Filing
Jul 19, 2024 3 Filing